Pfizer (PFE) Posted Positive Phase 3 Vitiligo Results For LITFULO

What happened: Pfizer (NYSE:PFE) reported positive Phase 3 results for oral LITFULO (ritlecitinib) in nonsegmental vitiligo, with meaningful facial and total body repigmentation and a favorable tolerability profile. Pfizer plans regulatory submissions across multiple regions. Key numbers: US$156.2 billion market cap. Why it matters: The data supports Pfizer's push to make immunology and dermatology non COVID growth engines. If approved, LITFULO would add a second indication in a different chronic skin condition, competing with Incyte and AbbVie.

Pfizer (NYSE:PFE) reported positive Phase 3 results for oral LITFULO (ritlecitinib) in nonsegmental vitiligo, with meaningful facial and total body repigmentation and a favorable tolerability profile. Pfizer plans regulatory submissions across multiple regions.

The data supports Pfizer's push to make immunology and dermatology non COVID growth engines. If approved, LITFULO would add a second indication in a different chronic skin condition, competing with Incyte and AbbVie.